← Back to Search
New Approaches To Treatment Of Various Cancers Based On Cytotoxic Analogs Of LHRH, Somatostatin And Bombesin.
A. Schally, Attila János Nagy
Published 2003 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The development of targeted cytotoxic analogs of hypothalamic peptides for the therapy of various cancers is reviewed and various oncological studies on experimental tumors are summarized. Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. The same radicals have been incorporated into cytotoxic analogs of somatostatin which can be also targeted to receptors for this peptide in prostatic, mammary, ovarian, renal and lung cancers, brain tumors and their metastases. A targeted cytotoxic analog of bombesin containing 2-pyrrolino-DOX has also been synthesized and successfully tried in experimental models of prostate cancer, small cell lung carcinoma and brain tumors. The development of these new classes of peptide analogs should lead to a more effective treatment for various cancers.
This paper references
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
A. Nagy (2000)
Targeted cytotoxic analogue of bombesin/ gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice
H. Kiaris (1999)
Effective treatment of advanced estrogen–independent MXT mouse mammary cancers with targeted cytotoxic LH–RH analogs
K. Szepesházi (2004)
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
A. Nagy (1996)
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
E. Krenning (2004)
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207
J. M. Arencibia (2002)
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
H. Kiaris (2001)
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
A. Płonowski (1999)
Peptide analogs in the therapy of prostate cancer
A. Schally (2000)
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.
N. Benali (2000)
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
M. Miyazaki (1999)
Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.
R. Cai (1994)
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
G. Halmos (2000)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
J. Klijn (2000)
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
M. Koppán (1998)
Presence of receptors for bombesin/gastrin‐releasing peptide and mRNA for three receptor subtypes in human prostate cancers
B. Sun (2000)
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
G. Emons (1994)
Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
G. Srkalović (1998)
RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors
G. Halmos (2000)
Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
G. Srkalović (1990)
Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆
A. Schally (1999)
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
G. Halmos (1999)
Targeted cytotoxic somatostatin analogs: A modern approach to the therapy of various cancers
A. Nagy (2001)
Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer.
S. P. Shriver (2000)
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
M. Miyazaki (1997)
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
R. Markwalder (1999)
Molecular pharmacology of somatostatin receptor subtypes
Y. Patel (1997)
Somatostatin receptors in human renal cell carcinomas.
J. Reubi (1992)
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
L. Buscail (1996)
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
M. Kovács (1997)
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
G. Emons (1993)
Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapy
A. Nagy (2002)
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
C. Gründker (2002)
Oncological applications of somatostatin analogues.
A. Schally (1988)
Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238
Z. Kahan (1999)
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
K. Szepesházi (2002)
The role of somatostatin and its analogs in the diagnosis and treatment of tumors.
S. Lamberts (1991)
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
L. Chatzistamou (2000)
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
G. Halmos (2000)
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
R. Cai (1986)
Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
G. Irmer (1995)
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215
Z. Szereday (2002)
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
Z. Kahán (2004)
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
H. Kiaris (2000)
Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.
A. Jungwirth (1997)
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
A. Płonowski (2002)
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
A. Nagy (1997)
Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
P. Limonta (1992)
Hypothalamic Hormones and Cancer
A. Schally (2001)
Inhibition of the UCI‐107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN‐238
A. Płonowski (2001)
Targeted cytotoxic analog of luteinizing hormone‐releasing hormone AN‐207 inhibits the growth of PC‐82 human prostate cancer in nude mice
M. Koppán (1999)
Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207
Z. Kahan (1999)
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
S. Radulovic (1992)
Targeted Cytotoxic Analogue of Luteinizing Hormone‐Releasing Hormone (LH‐RH) Only Transiently Decreases the Gene Expression of Pituitary Receptors for LH‐RH
M. Kovács (2002)
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
A. Schally (1999)
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
K. Szepesházi (2001)
Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective.
M. J. Karten (1986)
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.
W. Bauer (1982)
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
A. Płonowski (2000)
Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease.
M. Sunday (1988)
Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer
M. Fekete (1989)
in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215
A. Płonowski (2000)
Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
D. Dondi (1994)
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
A. Nagy (1998)
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
F. Cuttitta (1985)
This paper is referenced by
Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.
L. Hofland (2005)
Prodrug-based intracellular delivery of anticancer agents.
L. Bildstein (2011)
Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer
A. Schally (2010)
Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide
A. Taheri (2011)
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
M. Letsch (2004)
Peptides and Proteins Increase Mineral Absorption and Improve Bone Condition
H. Kawakami (2011)
Gonadotropin‐releasing hormone receptor‐targeted paclitaxel–degarelix conjugate: synthesis and in vitro evaluation
C. Wang (2015)
Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)
J. Engel (2012)
Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins
A. Ben-Yehudah (2004)
Complete objective response to biological therapy of plurifocal breast carcinoma.
G. Di Bella (2008)
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
J. Engel (2005)
A Phase II Trial of AEZS‐108 in Castration‐ and Taxane‐Resistant Prostate Cancer
S. Yu (2017)
Proteins and peptides as anticancer agents
H. Panda (2011)
The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer.
G. D. Bella (2011)
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone‐releasing hormone analog AN‐207
A. Stangelberger (2006)
Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.
M. Manea (2011)
In vitro capability of multi-walled carbon nanotubes modified with gonadotrophin releasing hormone on killing cancer cells
Bo-Zhang Yu (2007)
Effects of a GnRH cytotoxin on reproductive function in peripubertal male dogs.
B. Ball (2006)
Phase I Trial on sms‐D70 Somatostatin Analogue in Advanced Prostate and Renal Cell Cancer
T. Joensuu (2004)
Receptor-mediated tumor targeting based on peptide hormones
G. Mező (2010)
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.
K. Brown (2010)
Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms
A. Frilling (2007)
Oxygen adsorption by carbon nanotubes and its application in radiotherapy.
J. Yang (2007)
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)
C. W. Kwok (2014)
Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
I. van den Broek (2008)
Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system
Andreas R. Gumlnthert (2004)
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
G. Keller (2006)
Single Case of a Complete Response in a Metastatic Urothelial Carcinoma Patient Treated with Zoptarelin Doxorubicin
Gustavo Fernandez-Castro (2014)
Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215
J. Engel (2005)
Characterization of the bombesin-like peptide receptor family in primates.
H. Sano (2004)
Possibilities to increase the effectiveness of doxorubicin in cancer cells killing
V. Hanušová (2011)
Cytotoxic conjugates of peptide hormones for cancer chemotherapy
Lichun Sun (2008)See more